IMPORTANT ESPERION SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Class Action Lawsuit Has Bee...
January 22 2016 - 6:30PM
Wolf Haldenstein Adler Freeman & Herz LLP announces that a
class action lawsuit has been filed in the United States District
Court for the Eastern District of Michigan on behalf of all
shareholders who purchased shares of Esperion Therapeutics, Inc.
("Esperion") (NASDAQ:ESPR) between August 18, 2015 and September
28, 2015, inclusive (the “Class Period”).
Shareholders who incurred losses on
shares purchased within the Class Period are urged to contact the
firm immediately at classmember@whafh.com or (800)
575-0735 or (212) 545-4774.
If you purchased the shares of Esperion
Therapeutics, Inc. during the period August 18, 2015 and September
28, 2015, inclusive, you may, no later than March 14,
2016, request that the Court appoint you as lead plaintiff
of the proposed class.
The filed complaint alleges that Defendants
issued false and misleading statements regarding the Company's
business and prospects, including that there was no clear path to
approval for ETC-1002, the Company's lead product candidate
designed to lower LDL-cholesterol levels, and that the FDA had
encouraged the Company to initiate a cardiovascular outcomes trial
("CVOT") and that completion of a CVOT could be necessary prior to
approval of ETC-1002.
On August 17, 2015, Esperion reported to
investors material events from an August 2015 meeting with the FDA;
the Company stated that during the meeting it was informed by the
FDA that the Company would not have to complete a CVOT to gain
approval of ETC-1002.
Then in a September 28, 2015 news release, the
Company noted that the FDA had actually "encouraged the Company to
initiate a cardiovascular outcomes trial promptly" and it may be
necessary to have a completed CVOT prior to approval. Following
this disclosure, shares of Esperion common stock fell $16.76 per
share, a decline of 47%, to close on September 29, 2015 at $18.33
per share.
Wolf Haldenstein has extensive experience in the
prosecution of securities class actions and derivative litigation
in state and federal trial and appellate courts across the country.
The firm has attorneys in various practice areas; and offices in
New York, Chicago and San Diego. The reputation and expertise of
this firm in shareholder and other class litigation has been
repeatedly recognized by the courts, which have appointed it to
major positions in complex securities multi-district and
consolidated litigation.
If you wish to discuss this action or have any
questions regarding your rights and interests in this case, please
immediately contact Wolf Haldenstein Adler Freeman & Herz LLP
by telephone at (800) 575-0735, via e-mail at
classmember@whafh.com, or visit our website at
www.whafh.com. All e-mail correspondence should make reference
to the “Esperion Investigation.”
Attorney Advertising. Prior results do not guarantee or predict
a similar outcome.
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024